Cyclin D1: polymorphism, aberrant splicing and cancer risk.
The cyclin D1 proto-oncogene exercises powerful control over the mechanisms that regulate the mitotic cell cycle, and excessive cyclin D1 expression and/or activity is common in human cancers. Although somatic mutations of the cyclin D1 locus are rarely observed, mounting evidence demonstrates that a specific polymorphism of cyclin D1 (G/A870) and a protein product of a potentially related alternate splicing event (cyclin D1b) may influence cancer risk and outcome. Herein, we review the epidemiological and functional literatures that link these alterations of cyclin D1 to human tumor development and progression.
Knudsen
K E
KE
Department of Cell Biology, University of Cincinnati, Cincinnati, OH 45267, USA. erik.knudsen@uc.edu
Diehl
J Alan
JA
Haiman
C A
CA
Knudsen
E S
ES
D017398:Alternative Splicing; D002453:Cell Cycle / Q000502:physiology; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D019938:Cyclin D1 / Q000235:genetics* / Q000502:physiology; D018450:Disease Progression; D016021:Epidemiologic Studies; D006801:Humans; D009369:Neoplasms / Q000453:epidemiology* / Q000235:genetics* / Q000503:physiopathology; D011110:Polymorphism, Genetic; D000090063:Proto-Oncogene Mas
C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D019938:Cyclin D1